Close

Synergy Pharma (SGYP) Files IND for SP-333

September 12, 2012 8:40 AM EDT
Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) announced that an Investigational New Drug (IND) application was submitted on September 7, 2012 for clinical evaluation of SP-333 to treat inflammatory bowel disease (IBD). SP-333 is a second-generation guanylate cyclase-C (GC-C) agonist with the potential to treat GI disorders and diseases.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA